HEALTHJun 14 · 06:28 UTCSCIENCE DAILY

People taking GLP-1 weight loss drugs like Ozempic started moving less

People taking GLP-1 weight-loss drugs like Ozempic, Wegovy, Mounjaro, and Zepbound may experience reduced physical activity despite weight loss, according to Fitbit data analysis. Researchers noted declines in daily steps and exercise levels, raising concerns about muscle mass loss and long-term health impacts.

Nexus surfaces and summarizes. The full story lives at the source.

Mentioned

OzempictopicWegovytopicMounjarotopicZepboundtopicFitbitorganizationGLP-1 weight loss drugstopicphysical activity declinetopicmuscle mass reductiontopiclong-term health concernstopic

Spot something wrong with this article?Report a problem →

Forward this

Related Signal

Adjacent reporting

HEALTHApr 9 · 07:09 UTC
The hidden tradeoff behind today’s most popular weight loss drugs
HEALTHMay 19 · 13:05 UTC
People who lost the most weight on Ozempic saw huge health benefits
HEALTHJun 2 · 13:29 UTC
Breaking down findings of new study on weight loss drugs and breast cancer
HEALTHMay 28 · 15:03 UTC
GLP-1 drugs linked to major slowdown in breast cancer, prostate cancer and more: new study
HEALTHApr 10 · 11:00 UTC
Divorce boom may follow use of Ozempic and other GLP-1 drugs, experts warn